Conflicts of interests (COIs) for the MSIF essential medicines panel (MEMP) were independently assessed by the The National Center for Clinical Excellence, Quality and Safety of Care (CNEC) of the Istituto Superiore di Sanità.
- ISS process for MEMP COI assessment
- ISS report on MEMP COI March 2022
- MEMP COI per DMT March 2022
- ISS report update May 2022
- MEMP COI update November 2022
MSIF COI statement 2023
Multiple Sclerosis International Federation (MSIF) is an alliance of national multiple sclerosis (MS) organisations. MSIF receives income from a wide range of sources, including healthcare and other companies, individuals, member organisations, campaigns, foundations and trusts. Over the last 5 years, MSIF received funding from the following companies: BristolMyersSquibb, Sanofi, Merck, Viatris (formerly Mylan), Novartis, Biogen and Roche – all of which is publicly disclosed. Our independence and all our donations from the healthcare industry are governed by our healthcare policy. MSIF has not received any funding from industry for its access to medicines work in 2019, 2020, 2021 or 2022.